Blood culture

Court Determines that Kurin Does Not Infringe Magnolia Medical Patent

Retrieved on: 
torsdag, maj 16, 2024
Biotechnology, Practice Management, Professional Services, Other Health, Health, General Health, Patent Law, Health Technology, Infectious Diseases, Hospitals, Legal, Patient, Judgement, Hospital, Patent, Blood culture, Infection, Court, District court, United States patent law

“Previously, on Dec. 1, 2023, the US Patent and Trademark Office issued a final rejection of these same two patent claims.

Key Points: 
  • “Previously, on Dec. 1, 2023, the US Patent and Trademark Office issued a final rejection of these same two patent claims.
  • This opinion by the Court confirms that even if these patent claims were valid, Kurin does not infringe them.
  • Kurin passively sidelines potential contaminants during blood culture collection.
  • Kurin Lock and Kurin Jet give clinicians the tools they need to address these problems.

Leveraging Active Diagnostic Stewardship Interventions to Optimize the Outcomes of Patients with Bacteremia, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
tisdag, maj 14, 2024
Patient, Disease, Antimicrobial stewardship, University, Blood culture, Doctor of Pharmacy, Fungal infection, Associate, Mortality, BCID, University of Pittsburgh, Nursing

TORONTO, May 14, 2024 /PRNewswire-PRWeb/ -- Bloodstream infections are a common cause of morbidity and mortality despite advances in antimicrobial agents and sepsis management. Over the past decade, several molecular methods have been integrated into routine clinical microbiology workflows due to their ability to rapidly and simultaneously detect microorganisms and antimicrobial resistance genes from positive blood cultures.

Key Points: 
  • The impact on clinical outcomes is only realized when rapid BCID results are partnered with active stewardship interventions.
  • However, the impact on clinical outcomes is only realized when rapid BCID results are partnered with active stewardship interventions.
  • Register for this webinar today to understand how active diagnostic stewardship interventions can help optimize the outcomes of patients with bacteremia.
  • For more information, or to register for this event, visit Leveraging Active Diagnostic Stewardship Interventions to Optimize the Outcomes of Patients with Bacteremia.

T2 Biosystems Announces First Quarter 2024 Financial Results

Retrieved on: 
måndag, maj 6, 2024
FDA, ASPR, International, Research, ECCMID, U.S. FDA, ATM, Panel, Blood culture, CRG, Acinetobacter baumannii, Infection, Journal, Growth, Sepsis

LEXINGTON, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced unaudited financial and operational results for the first quarter ended March 31, 2024.

Key Points: 
  • LEXINGTON, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced unaudited financial and operational results for the first quarter ended March 31, 2024.
  • Advanced the T2Resistance Panel toward U.S. FDA 510(k) submission, expected to occur during the third quarter of 2024.
  • “Looking ahead, we plan to launch T2Lyme Panel and file the FDA submission for the T2Resistance Panel during the third quarter of 2024.
  • The Company raised $2.2 million in net proceeds through ATM sales in the first quarter of 2024.

T2 Biosystems Announces New Publication Highlighting the Clinical Benefits and Performance of the T2Resistance Panel

Retrieved on: 
måndag, mars 18, 2024
CE marking, Panel, Patient, Journal, Blood culture, Data, FDA, Food, Medical imaging

LEXINGTON, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced the publication of a new study highlighting the clinical benefits and performance of real-world use of the T2Resistance® Panel in The Journal of Clinical Microbiology.

Key Points: 
  • LEXINGTON, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced the publication of a new study highlighting the clinical benefits and performance of real-world use of the T2Resistance® Panel in The Journal of Clinical Microbiology.
  • The European study demonstrated high accuracy for the T2Resistance Panel, faster detection times, and the impact of faster test results on clinical interventions based on T2 sepsis test results.
  • “This publication is the strongest demonstration to date of the clinical impact the T2Resistance Panel in a real-world hospital setting,” said John Sperzel, Chairman and CEO of T2 Biosystems.
  • Clinical Impact: Across 59 patients in the study, there were 49 clinical interventions, resulting in 17 antibiotic escalations and 32 discontinuations of unnecessary antibiotics.

Italy Automated Microbiology Market Report 2023-2028 - Growth Opportunities, 2023 Supplier Shares by Assay, Five-Year Segmentation Forecasts - ResearchAndMarkets.com

Retrieved on: 
fredag, april 5, 2024
Biotechnology, Health, Medical Devices, Blood culture, Emerging technologies, Assay, SWOT analysis, Microbiology, Retail

The "2023-2028 Italy Automated Microbiology Market - Growth Opportunities, 2023 Supplier Shares by Assay, Five-Year Segmentation Forecasts - Competitive Strategies and SWOT Analysis, Instrumentation Pipeline, Emerging Technologies, Market Barriers and Risks" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "2023-2028 Italy Automated Microbiology Market - Growth Opportunities, 2023 Supplier Shares by Assay, Five-Year Segmentation Forecasts - Competitive Strategies and SWOT Analysis, Instrumentation Pipeline, Emerging Technologies, Market Barriers and Risks" report has been added to ResearchAndMarkets.com's offering.
  • This report is an analysis of the major business opportunities emerging in the automated microbiology market during the next five years.
  • The report examines key trends in the Italian automated microbiology market; reviews current and emerging assays; analyzes potential applications of innovative diagnostic technologies; forecasts volume and sales for molecular diagnostic, microbial identification, antibiotic susceptibility, blood culture, urine screening and immunodiagnostic procedures, as well as over 100 infectious disease tests by assay, application, market segment, profiles leading players and potential market entrants; and suggests alternative business expansion strategies for suppliers.

Kurin, Inc. Reports Record Revenue for Q1 2024

Retrieved on: 
onsdag, april 3, 2024
Biotechnology, Health, Medical Devices, Professional, Blood culture, Patient, Kurin, Forecasting, CMS, Infection

Kurin, Inc., the inventor and manufacturer of Kurin® blood culture collection sets, announced record revenues for the first quarter of 2024, following a record 2023.

Key Points: 
  • Kurin, Inc., the inventor and manufacturer of Kurin® blood culture collection sets, announced record revenues for the first quarter of 2024, following a record 2023.
  • Despite a challenging healthcare environment, revenue in Q1 was ~30% higher than Q1 2023 and ~8% higher than Q4 2023, which was also a record quarter for Kurin.
  • Kurin Lock® and Kurin Jet™ both sideline potential contaminants during blood culture collection and provide a better and more sustainable approach than active, conventional mechanical diversion.
  • Kurin Lock and Kurin Jet give clinicians the tools they need to address these problems.

T2 Biosystems Announces FDA 510(k) Submission to Expand Use of the FDA-Cleared T2Candida Panel to Include Pediatric Testing

Retrieved on: 
onsdag, januari 3, 2024
Candida tropicalis, Food, FDA, Candidiasis, Disease, Mortality, Blood, Candida glabrata, Candida krusei, Bambino, Candida albicans, Candida parapsilosis, Patient, Diagnosis, Journal, Blood culture

The T2Candida Panel is the only FDA-cleared diagnostic test able to detect sepsis-causing Candida pathogens directly from blood, in just 3-5 hours, without the need to wait days for a positive blood culture.

Key Points: 
  • The T2Candida Panel is the only FDA-cleared diagnostic test able to detect sepsis-causing Candida pathogens directly from blood, in just 3-5 hours, without the need to wait days for a positive blood culture.
  • The T2Candida Panel runs on the FDA-cleared T2Dx® Instrument and simultaneously detects five Candida species – including Candida albicans, Candida tropicalis, Candida parapsilosis, Candida krusei, and Candida glabrata.
  • The study also found a higher detection rate with the T2Candida Panel as six additional probable or possible fungal bloodstream infections in pediatric patients were detected by the T2Candida Panel and missed by blood culture.
  • T2Candida was the only test recommended for individual use as a tool for the diagnosis of invasive candidiasis in at-risk children and adolescents.

Accelerate Diagnostics Announces Collaboration for the Use of the Arc™ System in Combination With Bruker´s MALDI Biotyper®

Retrieved on: 
måndag, november 27, 2023
Economics, Pressure, Microbiology, Clinical trial, Sepsis, FDA, Laboratory, BRKR, MALDI, Blood culture, Acceleration, Sirius (instrumental), Legislation, Fine chemical, Medical device, Bruker

TUCSON, Ariz., Nov. 27, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) an innovator of rapid in vitro diagnostics in microbiology, announced the signing of a collaboration and quality agreement with Bruker Corporation (NASDAQ: BRKR), the provider of the market-leading MALDI Biotyper system for microbial identification. This agreement enables both companies to validate the use of Accelerate Diagnostics' Arc™ system, an innovative, automated positive blood culture sample preparation platform, with Bruker's MALDI Biotyper® sirius instruments and Sepsityper® software for subsequent registration in both the US and EMEA markets.

Key Points: 
  • Designed for clinical laboratories, the Arc™ system has a simple load-and-go workflow that automates direct from positive blood culture sample preparation for downstream microbial identification using Bruker's MALDI Biotyper system.
  • The Arc™ system enables on-demand processing of samples without the need for an overnight culture incubation, reducing the wait time for identification results.
  • "The combination of Bruker's MALDI Biotyper with Accelerate Diagnostics' Arc™ system to automate positive blood culture sample preparation and rapid microbial identification will be a valuable addition to many laboratories.
  • Bruker welcomes this collaboration with Accelerate Diagnostics as both companies are committed to help laboratories in the important fight against sepsis with their leading products" said Wolfgang Pusch, President, Bruker Microbiology & Infection Diagnostics.

Magnolia Medical Technologies Marks World AMR Awareness Week by Recognizing the Need to Reduce Antibiotic Usage through Accurate Blood Culture Results

Retrieved on: 
måndag, november 20, 2023
Select, CDI, Safety, Entrepreneurship, Fungal infection, WHO, AVP, Risk, Government, RN, WAAW, Sepsis, Patient, Infection, Antimalarial medication, Death, Drug resistance, Health, AMR, Invention, Acute kidney injury, Cancer, Diagnosis, Blood culture, Antimicrobial resistance, Hospital, Clostridioides difficile infection, Public, Education, Bloodstream infections, Pharmaceutical industry, Nursing

SEATTLE, Nov. 20, 2023 /PRNewswire/ -- In observance of World AMR Awareness Week (WAAW), Magnolia Medical Technologies, Inc., the inventors of the Steripath® Initial Specimen Diversion Device® (ISDD®) and the ISDD market to prevent false-positive sepsis tests, is driving efforts to highlight the role of diagnostic stewardship in combating the risk of AMR.

Key Points: 
  • Accurate blood culture results prevent patients from receiving unnecessary, prolonged, and potentially harmful antibiotic therapies, and associated preventable clinical complications, including acute kidney injury, Clostridioides difficile infection (CDI), and multidrug-resistant organism (MDRO) infections.
  • We recently completed a survey of over 1,000 Americans that highlighted the public and medical community's concern with the issue of AMR."
  • Magnolia Medical is encouraging everyone to "Go Blue" from November 18 to 24 to raise awareness for AMR and the need for continued education of this issue.
  • Please visit VoicesofSepsis.org to encourage action from your congressional representatives to support patient safety measures that also help combat the threat of AMR.

Oxford Nanopore and Day Zero Diagnostics Partner to Develop a New Class of Bloodstream Infection Diagnostics

Retrieved on: 
tisdag, november 14, 2023
World Health Organization, ID, Research, ONT, WHO, Risk, Oxford Nanopore Technologies, Mortality, Sepsis, Patient, Death, FDA, DZD, Workflow, Diagnosis, Infection, Blood culture, Nanopore sequencing, Day Zero, Health, Hospital, Collaboration, Bloodstream infections, Vaccine, Medical device, Fine chemical

According to the World Health Organization (WHO), there are 11 million sepsis-related deaths every year, accounting for one in five deaths worldwide.

Key Points: 
  • According to the World Health Organization (WHO), there are 11 million sepsis-related deaths every year, accounting for one in five deaths worldwide.
  • Early and effective treatment is paramount in a severe infection because the risk of mortality can increase by the hour.
  • "We are pleased to launch this collaboration with Oxford Nanopore that integrates nanopore sequencing innovations with Day Zero Diagnostics' platform technologies to develop a first-of-its kind diagnostic solution for sepsis," said Jong Lee, CEO and co-founder of Day Zero Diagnostics.
  • "We are excited to partner with Day Zero Diagnostics to bring the benefits of nanopore sequencing to fight bloodstream infections," said Gordon Sanghera, CEO of Oxford Nanopore Technologies.